Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luisa Guidi

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Inflammatory Bowel Diseases|July 2, 2014
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitisAlessandro Armuzzi, Daniela Pugliese, Silvio Danese, et al.
Radiology|December 14, 2011
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activityAntonio De Franco, Alessandra Di Veronica, Alessandro Armuzzi, et al.
Biomed Research International|September 25, 2013
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agentsLuisa Guidi, Carla Felice, Annabella Procoli, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2020
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patientsLorenzo Bertani, Domenico Tricò, Daniela Pugliese, et al.
United European Gastroenterology Journal|November 9, 2019
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel diseaseLuisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, et al.
Expert Opinion on Biological Therapy|October 19, 2020
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patientsDaniela Pugliese, Luisa Guidi, Giuseppe Privitera, et al.
Journal of Crohn'S & Colitis|July 17, 2020
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel DiseaseGiuseppe Privitera, Sara Onali, Daniela Pugliese, et al.
Journal of Crohn'S & Colitis|January 30, 2014
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomyRita Monterubbianesi, Annalisa Aratari, Alessandro Armuzzi, et al.
European Journal of Gastroenterology & Hepatology|June 23, 2009
Internet use among inflammatory bowel disease patients: an Italian multicenter surveyErika Angelucci, Ambrogio Orlando, Sandro Ardizzone, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 10, 2017
Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD studyMarco Daperno, Aurora Bortoli, Anna Kohn, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Inflammatory Bowel Diseases|July 2, 2014
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitisAlessandro Armuzzi, Daniela Pugliese, Silvio Danese, et al.
Radiology|December 14, 2011
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activityAntonio De Franco, Alessandra Di Veronica, Alessandro Armuzzi, et al.
Biomed Research International|September 25, 2013
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agentsLuisa Guidi, Carla Felice, Annabella Procoli, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2020
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patientsLorenzo Bertani, Domenico Tricò, Daniela Pugliese, et al.
United European Gastroenterology Journal|November 9, 2019
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel diseaseLuisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, et al.
Expert Opinion on Biological Therapy|October 19, 2020
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patientsDaniela Pugliese, Luisa Guidi, Giuseppe Privitera, et al.
Journal of Crohn'S & Colitis|July 17, 2020
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel DiseaseGiuseppe Privitera, Sara Onali, Daniela Pugliese, et al.
Journal of Crohn'S & Colitis|January 30, 2014
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomyRita Monterubbianesi, Annalisa Aratari, Alessandro Armuzzi, et al.
European Journal of Gastroenterology & Hepatology|June 23, 2009
Internet use among inflammatory bowel disease patients: an Italian multicenter surveyErika Angelucci, Ambrogio Orlando, Sandro Ardizzone, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 10, 2017
Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD studyMarco Daperno, Aurora Bortoli, Anna Kohn, et al.
Pageof 7